Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Glaucoma treatment: by the highest level of evidence.

× No keyword cloud information.

9 in total

Review 1. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.

Authors: Paul L Kaufman
Journal: Expert Opin Pharmacother Date: 2017-02-20 Impact factor: 3.889

2. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.

Authors: Robert N Weinreb; Jeffrey M Liebmann; Keith R Martin; Paul L Kaufman; Jason L Vittitow
Journal: J Glaucoma Date: 2018-01 Impact factor: 2.503

3. A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study.

Authors: Thomas R Walters; Angela C Kothe; José L Boyer; Dale W Usner; Krisol Lopez; Brigitte Duquesroix; Robert D Fechtner; Tomas Navratil
Journal: J Glaucoma Date: 2022-04-06 Impact factor: 2.290

4. Twenty-Four-Hour Variation of Intraocular Pressure in Primary Open-Angle Glaucoma Treated with Triple Eye Drops.

Authors: Yoshinori Itoh; Kenji Nakamoto; Hiroshi Horiguchi; Shumpei Ogawa; Takahiko Noro; Makoto Sato; Tadashi Nakano; Hiroshi Tsuneoka; Noriko Yasuda
Journal: J Ophthalmol Date: 2017-05-03 Impact factor: 1.909

5. Estimating three-dimensional outflow and pressure gradients within the human eye.

Authors: David W Smith; Chang-Joon Lee; William Morgan; Bruce S Gardiner
Journal: PLoS One Date: 2019-04-09 Impact factor: 3.240

Review 6. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.

Authors: Murray Fingeret; Ian B Gaddie; Marc Bloomenstein
Journal: Clin Exp Optom Date: 2019-01-07 Impact factor: 2.742

7. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study.

Authors: Shunsuke Nakakura; Akiyasu Kanamori; Yasuko Fukuma; Seita Wakabayashi; Yuki Nagata; Miku Adachi
Journal: BMJ Open Date: 2021-01-29 Impact factor: 2.692

8. PnPP-19 Peptide as a Novel Drug Candidate for Topical Glaucoma Therapy Through Nitric Oxide Release.

Authors: Carolina Nunes da Silva; Lays Fernanda Nunes Dourado; Maria Elena de Lima; Armando da Silva Cunha-Jr
Journal: Transl Vis Sci Technol Date: 2020-07-22 Impact factor: 3.283

9. ReGAE 12: preventing glaucoma blindness in the Caribbean through implementation of the Moorfields Safer Surgery System and skills transfer from the UK to Trinidad and Tobago.

Authors: Desirée Murray; Peter Shah
Journal: Clin Ophthalmol Date: 2018-09-11

9 in total